# TRANSCODE THERAPEUTICS INC (RNAZ)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/RNAZ/

- Reporting holders: 9
- Reported value: $217.6K
- Shares held by institutions: 35,039 of 16,930,739 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Yorkville Advisors Global, LP](https://holderbook.com/funds/1838613-yorkville-advisors-global-lp/) | $122.0K | 19,639 | 0.1% | 1 |
| [VANGUARD CAPITAL MANAGEMENT LLC](https://holderbook.com/funds/2100119-vanguard-capital-management-llc/) | $40.6K | 6,545 | 0.0% | 2 |
| [VANGUARD FIDUCIARY TRUST CO](https://holderbook.com/funds/933478-vanguard-fiduciary-trust-co/) | $18.5K | 2,982 | 0.0% | 2 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $17.9K | 2,888 | 0.0% | 3 |
| [MERCER GLOBAL ADVISORS INC /ADV](https://holderbook.com/funds/853758-mercer-global-advisors-inc-adv/) | $9.5K | 1,535 | 0.0% | 1 |
| [FMR LLC](https://holderbook.com/funds/315066-fmr-llc/) | $4.4K | 706 | 0.0% | 1 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $4.2K | 677 | 0.0% | 5 |
| [WELLS FARGO & COMPANY/MN](https://holderbook.com/funds/72971-wells-fargo-company-mn/) | $342 | 55 | 0.0% | 2 |
| [SBI Securities Co., Ltd.](https://holderbook.com/funds/1851815-sbi-securities-co-ltd/) | $75 | 12 | 0.0% | 5 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 9 | $217.6K |
| Q1 2026 | 7 | $266.2K |
| Q4 2025 | 5 | $26.4K |
| Q3 2025 | 7 | $155.0K |
| Q2 2025 | 8 | $237.0K |
| Q1 2025 | 16 | $1.1M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 14 | $263.0K |
| Q1 2024 | 6 | $284.1K |
| Q4 2023 | 12 | $105.4K |
| Q3 2023 | 10 | $281.6K |